PulseAugur
EN
LIVE 20:20:40
中文(ZH) 百济神州：2026年第一季度净利润16.08亿元

BeiGene posts Q1 profit of 1.6B yuan on strong drug sales

By PulseAugur Editorial · [1 sources] ·

BeiGene announced its financial results for the first quarter of 2026, reporting a net profit attributable to parent company owners of 1.608 billion yuan. This marks a significant turnaround from a loss in the same period last year. The company's revenue grew by 31.0% year-over-year to 10.544 billion yuan, primarily driven by strong sales of its key products, including BeiYueZe®, authorized products from Amgen, and BeiZeAn®. AI

RANK_REASON Financial results announcement from a major company. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

BeiGene posts Q1 profit of 1.6B yuan on strong drug sales

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Financial results announcement from a major company. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
154 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    BeiGene: Net profit of 1.608 billion yuan in the first quarter of 2026

    36氪获悉，百济神州公告，公司2026年第一季度实现营业总收入105.44亿元，同比增长31.0%；产品收入103.21亿元，同比增长29.3%；归属于母公司所有者的净利润16.08亿元，上年同期为亏损。业绩增长主要得益于百悦泽®、安进公司授权产品及百泽安®的销售增长。

RELATED ENTITIES

RELATED TOPICS